ImClone Systems shares Jump
Tuesday, September 11, 2007
Shares of ImClone Systems are trading extremely well today rasing more than 16% with a huge volume, after ImClone Systems and Bristol-Myers Squibb said that a Phase III study of Erbitux combined with platinum-based chemotherapy met its primary endpoint of increasing overall patient survival compared with chemotherapy alone in patients with advanced non-small-cell lung cancer. Looking at thge technical chart, ImClone stock made a new 52 week year today at $47.22, however is at this moment losing some ground far from this level. Overall, stock is in a Bull Market with all indicators showing a strong performance. RSI is actually in overbought conditions, so stock should pull back some of the recent gains, but the picture are still equal, Bull Market.
Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations. The charts provided here are not meant for investment purposes and only serve as technical examples.
Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations. The charts provided here are not meant for investment purposes and only serve as technical examples.
Labels: IMCL
